Loading stock…

Roivant Sciences Ltd. (ROIV) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Roivant Sciences Ltd.

ROIVMarket cap $26BPrice $35.5

Country🇬🇧United Kingdom

SectorHealthcare

IndustryBiotechnology

Builds biotech startups called "Vants," each spun off to develop a single drug candidate through clinical trials. Roivant then sells or partners the winners, turning drug development into a repeatable, portfolio-style business instead of a one-shot gamble.

In Bastion Portfolios?

52W Return+106%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-36%1

Revenue Forecast

Rev CAGR (1y)+571%10

Rev CAGR (3y)+462%10

Rev CAGR (5y)+268%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-18102%1

Net Income Margin-3535%1

Free Cash Flow Margin-10901%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-6%2

ROA-8%1

Earnings Stability22

GEAR+VERY WEAK14

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV6.13

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-3.2%2

Dividend Yieldna–

Momentum

Short term

1 month return+2%8

3 month return-2%6

YTD return+64%10

Mid term

Price vs 52wHigh84%6

1 year return+120%10

Long term

3 year return+229%9

5 year return+475%10

Risk Shield

Price Risk

Beta0.85

Volatility44%4

Free Cash Flow

Free Cash Flow Margin-10901%1

Free Cash Flow Yield-3.2%2

Quality

ROCE-27%1

Earnings Stability22

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

ROIVRoivant Sciences

Revenue FY26$8.3M

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-36%1

Revenue, next 1Y+571%10

Revenue, next 3Y, CAGR+462%10

Revenue, next 5Y, CAGR+268%10

EARNINGS FORECAST▾SCORE

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

EPS growth, FY29ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue is set to grow 462%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 462%/yr from here.

The runway holds up: revenue is set to grow 268%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 36%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

ROIVRoivant Sciences

Total return Current263%

Price return Current263%

MOMENTUM RATING↗

VERY STRONG87 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return-2%6

YTD return+64%10

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+120%10

3-year return+229%9

5-year return+475%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +229% over three years and +475% over five, ahead of 90% of the market.

It's up 120% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%) and so far this year (+64%).

WATCH

Returns sit at the market level over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Roivant Sciences. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ROIVRoivant Sciences

Revenue FY26$8.3M

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-36%1

Revenue, next 1Y+571%10

Revenue, next 3Y, CAGR+462%10

Revenue, next 5Y, CAGR+268%10

EARNINGS FORECAST▾SCORE

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

EPS growth, FY29ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue is set to grow 462%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 462%/yr from here.

The runway holds up: revenue is set to grow 268%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 36%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

ROIVRoivant Sciences

Total return Current263%

Price return Current263%

MOMENTUM RATING↗

VERY STRONG87 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return-2%6

YTD return+64%10

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+120%10

3-year return+229%9

5-year return+475%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +229% over three years and +475% over five, ahead of 90% of the market.

It's up 120% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%) and so far this year (+64%).

WATCH

Returns sit at the market level over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Roivant Sciences. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community